fda compounding semaglutide enforcement november 2025 news GLP-1 Weight Loss Drug in 2025: State Attorneys General Step into a Growing Regulatory Gap FDA Moves to Permanently Close

Importantly, the improvement in menstrual regularity was significantly correlated with weight loss, suggesting that while GLP-1 agonists may enhance reproductive outcomes, weight reduction plays a crucial role as well

The injection site may be numbed with a local anesthetic to minimize discomfort

Asperuloside alleviates lipid accumulation and inflammation in HFD-Induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome

At Tamazglobal, our editors have delved deep into the world of skin care and emerged with some favorites that promise not just glowing, but also healthier skin

Previous studies demonstrated that LRRK2 and PINK1 mutations promote dopaminergic neuronal toxicity

Liraglutide could reduce monthly migraine days Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat diabetes, appears to reduce monthly migraine days by more than half, researchers reported on June 20, 2025 at the annual European Academy of Neurology (EAN) Congress 25